Inducing Immune Tolerance with Glycan-Containing NSAAs: In Vivo & In Vitro Assays to Validate Efficacy
Time: 2:15 pm
day: Conference Day Two
Details:
- Understanding current approaches to treating autoimmune disease and attenuating immunogenicity of therapeutics broadly suppress the immune system
- Tolerizing patients to specific antigens is a holy-grail challenge that can displace systemic immunosuppression
- Illuminating the in vivo and in vitro assays used to validate efficacy for the immune tolerance approach
- Highlighting GROBio’s ProGly approach to immunotolerization enables reversal of autoimmune disease and elimination of anti-drug antibodies without systemic immunosuppression
